ebitda
950–1150 $million
FY 2025
official guidance
| Revenue | ₪6.8B |
|---|---|
| Operating income | ₪760.0M |
| Net income | ₪474.0M |
| Operating margin | 11.1% |
| Net margin | 6.9% |
| Return on equity | 7.4% |
| Period | 2025 |
OpenFilings analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Promising portfolio reset, but insufficient quantified milestones or risk-adjusted visibility to justify buying now.
Latest call · Q3 2025ICL delivered a solid quarter—sales rose 6% to $1.853 billion and adjusted EBITDA increased 4% to $398 million—but the investment case remains a hold rather than a buy.
The 2025 specialty-business EBITDA outlook is unchanged at $950 million-$1.15 billion, while the new growth strategy relies on unproven acquisitions, mix improvement and execution; sulfur inflation, weak Brazilian agriculture and the 2030 Dead Sea concession remain material risks.
Q4 should be broadly stable, with potash and phosphate prices holding relatively high and bromine prices firm, but rising sulfur costs are expected to pressure margins.
Brazilian farmer affordability, tight credit, high interest rates and potential disruption to China exports remain a risk to Growing Solutions volumes and profitability.
Improving potash production in Israel and Spain is an upside, though management did not provide a quantified earnings impact.
Specialty Crop Nutrition has grown from approximately $1 billion of sales and $60 million of EBITDA in 2020 to $2 billion and approximately $200 million in 2024; further mix shifts toward biostimulants, controlled-release fertilizers and nutrient-efficiency products could lift margins.
Specialty Food Solutions is being repositioned beyond phosphate-based ingredients into a much larger functional-food market, using organic R&D, partnerships and acquisitions. The opportunity is attractive, but capital allocation and acquisition returns are not yet defined.
Terminating downstream LFP cathode-material projects is a positive capital-discipline move and reduces investment exposure to falling battery-material prices, while retaining raw-material supply opportunities.
ICL's integrated potash, phosphate and bromine assets provide resource advantages, but the long-term moat depends heavily on winning an economically viable Dead Sea concession after 2030.
Management claims there is no global powerhouse in specialty fertilizers, but analysts received no concrete evidence of durable competitive differentiation, market-share targets or expected returns.
Management provided no tangible 2026 milestones, quantified cost savings, acquisition budget, return thresholds or timing for the new strategy despite direct analyst pushback.
The Dead Sea MOU provides approximately $2.54 billion of compensation plus salt-harvesting costs if ICL does not win the next concession, but ICL still faces a competitive tender and has not disclosed the economics of the future concession.
The specialty-growth plan is materially M&A-dependent across crop nutrition and food ingredients, creating execution, valuation and integration risk.
Specialty Crop Nutrition margins remain below legacy-business levels; management's aspiration to reach mid-double-digit EBITDA margins was not accompanied by a timeline or quantified bridge.
Brazil weakness is not merely timing-related: management cited tight credit, high real interest rates, farmer bankruptcies and lower affordability, with no confidence that conditions improve in Q4.
The LFP retreat highlights that prior growth investments could have destroyed value; the new AI and efficiency program is currently a broad initiative rather than a measurable earnings plan.
ebitda
950–1150 $million
FY 2025
official guidance
revenue growth
—
FY 2030
management target
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
ICL Group Ltd.
ICL Group Ltd.
ICL Group Ltd.
ICL Group Ltd.
ICL Group Ltd.
ICL Group Ltd.